July 3, 2020 / 6:36 AM / a month ago

BRIEF-Paion: US FDA Approval Of Remimazolam For Induction And Maintenance Of Procedural Sedation

July 3 (Reuters) - Paion AG:

* SAID ON THURSDAY U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION

* PAION WILL RECEIVE A MILESTONE PAYMENT OF EUR 15 MILLION FROM COSMO AND TIERED ROYALTIES ON NET SALES RANGING FROM 20% TO 25% Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below